Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 11, 2026, 8:34 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2257–2280 of 54,972 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Patient Clear all

Conditions: Malignant Pleural Mesothelioma
Interventions: OT-101; Drug
Lead sponsor: Oncotelic Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 63 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Myelodysplastic Syndromes
Interventions: Lenalidomide; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 2
States / cities: Scottsdale, Arizona • St Louis, Missouri

Conditions: Complex Regional Pain Syndromes
Interventions: Forward Looking InfraRed Camera; Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 85 Years
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 1
States / cities: New York, New York

Conditions: Acanthosis Nigricans, Hyperinsulinemia, Spectroscopic Analysis
Interventions: Metformin, Dietary Modification; Drug · Behavioral
Lead sponsor: Henry Ford Health System; Other
Eligibility: 11 Years and older
Enrollment: 9 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2009 – 2012
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Non Celiac Gluten Sensitivity
Interventions: High dose Gluten, Low dose Gluten, Lactose free placebo; Dietary Supplement
Lead sponsor: Thomas Jefferson University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Metabolic Acidosis
Interventions: Sodium bicarbonate, Tris-hydroxymethyl Aminomethane; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 21 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: End Stage Renal Disease
Interventions: 13-valent conjugate pneumococcal vaccine; Biological
Lead sponsor: Michigan State University; Other
Eligibility: 50 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Non-infectious Intermediate Uveitis, Non-infectious Posterior Uveitis, Non-infectious Panuveitis
Interventions: LFG316, Conventional Therapy; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2017
U.S. locations: 6
States / cities: Golden, Colorado • Marietta, Georgia • Cambridge, Massachusetts + 3 more

Conditions: Prostate Cancer
Interventions: white button mushroom extract, flow cytometry, immunologic technique, laboratory biomarker analysis, gas chromatography-mass spectrometry, pharmacological study; Drug · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: Male only
Enrollment: 36 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2021
U.S. locations: 2
States / cities: Duarte, California • South Pasadena, California

Conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
Interventions: trebananib, cytarabine, laboratory biomarker analysis, pharmacological study; Biological · Drug · Other
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2016
U.S. locations: 2
States / cities: Buffalo, New York • Rochester, New York

Conditions: Prostate Cancer
Interventions: panitumumab; Biological
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years to 120 Years · Male only
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2002 – 2004
U.S. locations: 2
States / cities: Los Angeles, California • Philadelphia, Pennsylvania

Conditions: Breast Cancer
Interventions: Taxotere/Docetaxel, Adriamycin/Cytoxan, doxorubicin; Drug
Lead sponsor: Mothaffar Rimawi; Other
Eligibility: 18 Years and older · Female only
Enrollment: 167 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2004 – 2016
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Carcinoma, Non-Small-Cell Lung, Squamous Cell Carcinoma of Head and Neck, Solid Carcinoma
Interventions: DM005; Drug
Lead sponsor: Doma Biopharmaceutical（Suzhou）Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 208 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Detroit, Michigan • Dallas, Texas • Fairfax, Virginia

Conditions: Kidney (Renal Cell) Cancer
Interventions: dTA/dBA C-arm fluoroscopy system with Dyna CT, DSA arteriogram- hepatic arteries, CO2 aortogram; Device · Procedure
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Stanford, California

Conditions: Multiple Sclerosis (MS), Relapsing Remitting Multiple Sclerosis
Interventions: ANK-700, Placebo; Drug
Lead sponsor: Anokion SA; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 15
States / cities: Cullman, Alabama • Phoenix, Arizona • Aurora, Colorado + 12 more

Conditions: Advanced Solid Tumor
Interventions: vilastobart (XTX101), Atezolizumab; Drug
Lead sponsor: Xilio Development, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 125 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 19
States / cities: Phoenix, Arizona • Duarte, California • Encinitas, California + 16 more

Conditions: Breast Carcinoma
Interventions: Laboratory Biomarker Analysis; Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2100
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Diabetes
Interventions: CO-IMPACT, PACT; Other
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 30 Years to 70 Years
Enrollment: 478 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 2
States / cities: Ann Arbor, Michigan • Pittsburgh, Pennsylvania

Conditions: Diabetic Macular Edema, Cataract
Interventions: Aflibercept injected Pre- and Post-operatively, Aflibercept injected intraoperatively; Drug
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Hypercholesterolaemia
Interventions: Alirocumab, Placebo, Lipid-Modifying Therapy (LMT), Antihyperglycemic Drug; Drug
Lead sponsor: Sanofi; Industry
Eligibility: 18 Years and older
Enrollment: 517 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2017
U.S. locations: 29
States / cities: Encino, California • Fresno, California • Oakland, California + 25 more

Conditions: Neuromuscular Blocks
Interventions: 2 mg/kg sugammadex, 0.07 mg/kg neostigmine; Drug
Lead sponsor: The Cleveland Clinic; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Myelodysplastic Syndromes
Interventions: thalidomide; Drug
Lead sponsor: Celgene Corporation; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2004
U.S. locations: 38
States / cities: La Jolla, California • Palm Springs, California • Rancho Mirage, California + 35 more

Conditions: Advanced Lung Non-Small Cell Carcinoma, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8
Interventions: Bintrafusp Alfa, Docetaxel; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 3
States / cities: Scottsdale, Arizona • Jacksonville, Florida • Rochester, Minnesota

Conditions: Malignant Neoplasm, Psychosocial Effects of Cancer and Its Treatment
Interventions: psychosocial assessment and care, educational intervention, communication skills training, questionnaire administration; Procedure · Other
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years to 30 Years
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2021
U.S. locations: 1
States / cities: Duarte, California

Search by objective public record fields.

OT-101 in Combination With Pembrolizumab in Subjects With Malignant Pleural Mesothelioma Failing to Respond to Checkpoint Inhibition

Lenalidomide for Myelodysplastic Syndrome Refractory to Hypomethylating Agents

Infrared Images for Spinal Cord Stimulation in Complex Regional Pain Syndrome Patients

Spectroscopic and Colorimetric Analysis of Acanthosis Nigricans in Patients With Hyperinsulinemia

Gluten Ingestion Biomarkers in Patients w Gluten Sensitivity and Healthy Controls Peptides in Patients With Non-celiac Gluten Sensitivity and Healthy Patients: A Placebo-controlled Study

A Study of Tris-Hydroxymethyl Aminomethane (THAM) Versus Sodium Bicarbonate in Cardiac Surgical Patients

Study Response of 13-valent Conjugate Pneumococcal Vaccine in Patients With End Stage Renal Disease

Safety,Tolerability and Efficacy of Intravitreal LFG316 in Patients With Active Non-infectious Intermediate-, posterior-or Panuveitis ,

White Button Mushroom Extract in Treating Patients With Recurrent Prostate Cancer After Local Therapy

Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia

Monoclonal Antibody Therapy in Treating Patients With Prostate Cancer

Taxotere and Adriamycin/Cytoxan (AC) Validation in Breast Cancer Patients

A Study of DM005 in Patients With Advanced Solid Tumors

Impact of C-arm CT in Decreased Renal Function Undergoing TACE for Tx of Hepato-Cellular Carcinoma

Assessment of ANK-700 in Patients With Relapsing Remitting Multiple Sclerosis

Vilastobart (XTX101) Monotherapy and Vilastobart and Atezolizumab Combination Therapy in Advanced Solid Tumors

Whole Exome Sequencing in Finding Causative Variants in Germline DNA Samples From Patients With Congestive Heart Failure Receiving Therapy for Breast Cancer

Caring Others Increasing EngageMent in PACT

Cataract DME - Peri vs. Intraop

Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insulin (ODYSSEY DM - Insulin)

Sugammadex Vs Neostigmine in Reversing Neuromuscular Blocks in Outpatient ERCP. A Randomized, Double-Blinded Trial

A Study to Access the Safety/Efficacy of Thalidomide in the Treatment of Anemia in Patients With Myelodysplastic Syndromes

Docetaxel With or Without Bintrafusp Alfa for the Treatment of Advanced Non-small Cell Lung Cancer

Psycho-Educational Program in Increasing Knowledge and Satisfaction and Decreasing Distress in Younger Patients With Cancer Receiving Treatment